Abstract
BackgroundAdjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have